Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/105922SSX2 ANTIGEN DERIVED SHORT PEPTIDES
WO 27.05.2022
Int.Class C07K 7/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Appl.No PCT/CN2021/132192 Applicant XLIFESC, LTD. Inventor LI, Yi
The present invention relates to SSX2 antigen derived short peptides, and in particular to SSX2 derived tumor antigen short peptides, complexes formed by the short peptides and MHC molecules, and uses of the short peptides and complexes. In addition, the present invention also relates to molecules bound to the short peptides or complexes described above, and uses of the molecules.
2.WO/2022/105847LONG-ACTING NERVE GROWTH FACTOR POLYPEPTIDES AND USES THEREOF
WO 27.05.2022
Int.Class C07K 14/48
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
48Nerve growth factor (NGF)
Appl.No PCT/CN2021/131614 Applicant STAIDSON (BEIJING) BIOPHARMACEUTICALS CO. , LTD. Inventor LI, Ping
Provided are long-acting nerve growth factor (NGF) polypeptides comprising from N-terminus to C-terminus an NGF moiety and an Fc moiety, methods of making, and uses thereof.
3.WO/2022/109477USE OF INSULIN-LIKE GROWTH FACTORS WITH GAMMA-CHAIN CYTOKINES TO INDUCE HOMEOSTATIC PROLIFERATION OF LYMPHOCYTES
WO 27.05.2022
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
Appl.No PCT/US2021/060574 Applicant UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED Inventor BRUSKO, Todd, Michael
Low-dose IL-2 has been proposed as a therapy to rectify regulatory T cell (Treg) fitness in type 1 diabetes (T1D). Identification of a combinatorial approach permits lower IL-2 dosing and avoids off-target effects. Insulin-like growth factor- 1 (IGF1) is a hormone that promotes immunoregulation. Disclosed are methods that synergizes IGF1 with IL-2 to expand Tregs. In vivo IL-2+IGF1 treatment expands murine Tregs to a greater extent than either agent alone. IGF1+IL- 2 treatment permits gene transfer in primary human Treg without the requirement for conventional activation stimuli, observing that IGF1+IL-2 maintains Treg naivety.
4.WO/2022/108471AGENT FOR TREATING AND PREVENTING ACUTE VIRAL RESPIRATORY INFECTIONS
WO 27.05.2022
Int.Class A61K 9/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
Appl.No PCT/RU2020/000623 Applicant BEKKER, German Petrovich Inventor BEKKER, German Petrovich
The invention relates to medicine and concerns a medicinal agent for treating and preventing influenza and other acute viral respiratory infections (AVRI) in nasal form. The technical result of the invention is a preparation with high antiviral activity in the form of a spray or drops, which can be taken intranasally. The preparation is a medicinal and prophylactic agent for protecting against AVRIs. It has been demonstrated using, as an example, influenza viruses A and B that the proposed agent has a highly protective effect in relation to acute viral respiratory infections. The essence of the invention is an agent in the form of a nasal spray or drops, comprising the antiviral oligopeptide Alloferon in combination with stabilizers and antiseptics. The agent is used to treat and prevent acute viral respiratory infections by means of intranasal administration.
5.WO/2022/108951USE OF ANNEXIN V TO IMPROVE THE PURITY, SOLUBILITY AND LONG-TERM STABILITY OF PHAGE SUSPENSIONS
WO 27.05.2022
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2021/059580 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor BLANKENBERG, Francis Gerard
Methods are provided for the prevention of aggregation, simple purification stabilization and preservation of phage preparations for the use of treating bacterial infections.
6.WO/2022/104712COMPOUND COMPOSITION HAVING EFFECT OF PROMOTING BONE HEALTH, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
WO 27.05.2022
Int.Class A61K 38/01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
01Hydrolysed proteins; Derivatives thereof
Appl.No PCT/CN2020/130483 Applicant CHENLAND NUTRITIONALS, INC. Inventor ZOU, Shengcan
A compound composition having the effect of promoting bone health, which consists of a traditional Chinese medicine extract, chicken cartilage collagen, magnesium, vitamin K2 and vitamin D3. The traditional Chinese medicine extract is a mixture of a Eucommia ulmoides extract, a Davallia mariesii extract and a Cuscuta chinensis Lam. extract, and the traditional Chinese medicine extract is obtained by heating, refluxing and extracting with ethanol. The present invention also relates to a preparation method for the compound composition and an application thereof in the preparation of health foods.
7.WO/2022/106842METHODS OF PRODUCING RECOMBINANT COMPLEMENT PROTEINS, VECTORS AND THERAPEUTIC USES THEREOF
WO 27.05.2022
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
Appl.No PCT/GB2021/053009 Applicant GYROSCOPE THERAPEUTICS LIMITED Inventor MARCHBANK, Kevin
Aspects of the present invention relate to the recombinant production of a mature complement system protein. Certain embodiments of the present invention relate to recombinant production of fully mature human complement Factor I protein (CFI). Included herein are details of an expression vector with which to recombinantly express fully mature human CFI from mammalian cells. Further disclosed are chromatography steps with which to purify recombinantly expressed CFI. Certain aspects of the present invention relate to the use of an expression system in gene therapy and the like. Certain embodiments of the present invention relate to use of said vector as a medicament, for example for use in the treatment of complement-mediated disorders.
8.WO/2022/109167MEMBRANE-ACTIVE PEPTIDES AND METHODS FOR REVERSIBLE BLOOD- BRAIN BARRIER OPENING
WO 27.05.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2021/059938 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor SEARSON, Peter, Charles
The present disclosure is directed to a composition or combination comprising at least one membrane- active peptide, such as melittin, and at least one therapeutic and/or diagnostic agent. Methods of using the membrane- active peptides of the disclosure to open a blood-brain barrier and to deliver a therapeutic and/or a diagnostic agent to a central nervous system (CNS) of a subject in need thereof are also provided. When administered as an intra-arterial injection into the cerebrovasculature, membrane-active peptides, such as melittin, support reversible blood-brain barrier opening without neurological damage.
9.WO/2022/106061PHARMACEUTICAL COMBINATIONS COMPRISING A PEPTIDE CXCR4 INHIBITOR AND A TAXANE FOR TREATING CANCER
WO 27.05.2022
Int.Class A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
Appl.No PCT/EP2021/025451 Applicant POLYPHOR AG Inventor ZIMMERMANN, Johann
The present invention relates to pharmaceutical combinations comprising a peptidic CXCR4 inhibitor and a taxane for use in a method for the prevention, delay of progression or treatment of cancer.
10.WO/2022/106976STABLE PHARMACEUTICAL FORMULATIONS OF SOLUBLE FGFR3 DECOYS
WO 27.05.2022
Int.Class A61K 38/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
Appl.No PCT/IB2021/060546 Applicant PFIZER INC. Inventor GUDINAS, Anthony Michael
The present invention relates to the field of pharmaceutical formulations of polypeptides. Specifically, the present invention relates to stable liquid and lyophilized formulations and their pharmaceutical preparation and use. This invention is exemplified by liquid and lyophilized formulations of a sFGFR3 polypeptide.